Trial reportJACC. Heart failure2013
The STICH trial (Surgical Treatment for Ischemic Heart Failure): mode-of-death results.
Trial report in JACC. Heart failure, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 128 citations in OpenAlex.
- Genome-wide association study meta-analysis provides insights into the etiology of heart failure and its subtypes.Nature genetics · 2025Pooled it
- Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis.Journal of the American Heart Association · 2020Pooled it
- Use of sacubitril/valsartan early after CABG.Open heart · 2024Trial
- Arrhythmia and Death Following Percutaneous Revascularization in Ischemic Left Ventricular Dysfunction: Prespecified Analyses From the REVIVED-BCIS2 Trial.Circulation · 2023Trial
- Classification of Heart Failure Events by Severity: Insights From the VICTORIA Trial.Journal of cardiac failure · 2023Trial
- CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy: 10-Year Follow-Up of the STICH Trial.JACC. Heart failure · 2019Trial
- Trial
- Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction.Journal of the American College of Cardiology · 2013Trial
- Survival and outcomes of coronary artery bypass grafting in patients with extremely low ejection fraction (≤20%): A systematic review and meta-analysis.JTCVS open · 2026Article
- The Impact of Risk Factors and Comorbidities on Heart Failure in the Aging Population.International journal of molecular sciences · 2026Review
- Impact of cardiohepatic syndrome on postoperative mortality in heart failure patients with reduced ejection fraction undergoing coronary artery bypass grafting.Journal of cardiothoracic surgery · 2026Article
- Predicting sudden cardiac death in heart failure with reduced ejection fraction.Heart failure reviews · 2026Review
- Guideline-directed medical therapy after revascularization and outcomes in ischaemic cardiomyopathy.ESC heart failure · 2025Article
- Total-Arterial Revascularization Is Superior in Heart Failure Patients with Reduced Ejection Fraction-A Propensity Score Matched Retrospective Multicenter Analysis.Medical sciences (Basel, Switzerland) · 2025Article
- The Role of Myocardial Revascularization in Ischemic Heart Failure in the Era of Modern Optimal Medical Therapy.Medicina (Kaunas, Lithuania) · 2025Review
- Investigation of Myocardial Substrate for Sudden Arrhythmic Death in Coronary Artery Disease Without Acute Coronary Thrombosis or Myocardial Infarction.Journal of the American Heart Association · 2025Article
- Optimizing Revascularization in Ischemic Cardiomyopathy: Comparative Evidence on the Benefits and Indications of CABG and PCI.Life (Basel, Switzerland) · 2025Review
- Multivessel coronary disease should be treated with coronary artery bypass grafting in all patients who are not (truly) high risk.JTCVS open · 2025Article
- Article
- Atherosclerotic features in patients with heart failure.Archives of medical science : AMS · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 1 country.
Funding
Abstract
objectivesThis study sought to assess the effect of the addition of coronary artery bypass grafting (CABG) to medical therapy on mode of death in heart failure.
backgroundAlthough CABG therapy is widely used in ischemic cardiomyopathy patients, there are no prospective clinical trial data on mode of death.
methodsThe STICH (Surgical Treatment for Ischemic Heart Failure ) trial compared the strategy of CABG plus medical therapy to medical therapy alone in 1,212 ischemic cardiomyopathy patients with reduced ejection fraction. A clinical events committee adjudicated deaths using pre-specified definitions for mode of death.
resultsIn the STICH trial, there were 462 deaths over a median follow-up of 56 months. The addition of CABG therapy tended to reduce cardiovascular deaths (hazard ratio [HR]: 0.83; 95% confidence interval [CI]: 0.68 to 1.03; p = 0.09) and significantly reduced the most common modes of death: sudden death (HR: 0.73; 95% CI: 0.54 to 0.99; p = 0.041) and fatal pump failure events (HR: 0.64; 95% CI: 0.41 to 1.00; p = 0.05). Time-dependent estimates indicate that the protective effect of CABG principally occurred after 24 months in both categories. Deaths post-cardiovascular procedures were increased in CABG patients (HR: 3.11; 95% CI: 1.47 to 6.60), but fatal myocardial infarction deaths were lower (HR: 0.07; 95% CI: 0.01 to 0.57). Noncardiovascular deaths were infrequent and did not differ between groups.
conclusionsIn the STICH trial, the addition of CABG to medical therapy reduced the most common modes of death: sudden death and fatal pump failure events. The beneficial effects were principally seen after 2 years. Post-procedure deaths were increased in patients randomized to CABG, whereas myocardial infarction deaths were decreased.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.